Pfizer announced on 17 March 2025 the appointment of David Lepoittevin as director for Belgium and Luxembourg.

The executive has more than 30 years’ experience in the pharmaceutical industry, including more than 20 spent at Pfizer. He joins the Brussels-based team after eight years as head of the vaccines unit in France and the primary care business unit in 2024.

In his new role, Lepoittevin will be responsible for driving the group’s commercial and strategic strategy in these two markets. “As country manager of one of the four largest pharmaceutical companies based in Belgium, he will also be a committed ambassador for the Belgian biopharma sector, advocating for an environment in which it can maintain and even increase its competitiveness,” said Pfizer in a statement.

“I am delighted to be joining this team of talented colleagues,” commented Lepoittevin. “I am passionate about ensuring that new technologies reach the patients who need them most. I look forward to working with the team to continue to focus on access to innovation in Belgium and Luxembourg.”

Pfizer has some 5,000 employees across four sites in the two countries.

This article in French.